AGA-111
- Generic Name
- AGA-111
A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Angitia Biopharmaceuticals
- Target Recruit Count
- 400
- Registration Number
- NCT06115512
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Angitia Biopharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05574543
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath